Skip to main content
. 2017 Dec 19;9(6):7148–7161. doi: 10.18632/oncotarget.23426

Figure 5. Comparisons of primary outcomes between studies using additional gemcitabine and studies using gemcitabine as replacement chemotherapy.

Figure 5

(A) Overall survival (additional gemcitabine chemotherapy), (B) Overall survival (gemcitabine replacement chemotherapy) (C) Progression free survival (additional gemcitabine chemotherapy), (D) Progression free survival (gemcitabine replacement chemotherapy), (E) Objective tumor response rate (additional gemcitabine chemotherapy), (F) Objective tumor response rate (gemcitabine replacement chemotherapy).